Imetelstat appears headed for approval after its US adcom turns into a damp squib.

First-in-human study initiations include Boundless Bio’s second asset, and an ADC from Tubulis.

The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.

Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.

The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.

Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.